Truly wonderful team! Pleas keep up the great work of behalf of our patients.
~Dr. Naveen Pemmaraju, MD Anderson
As part of our coverage from the 2016 American Society of Hematology (ASH) annual meeting, MPN experts Dr. Catriona Jamieson, Dr. John Mascarenhas, Dr. Stephen Oh and our own Andrew Schorr, gathered to discuss the latest updates on treatment and research.
What factors should you consider when deciding to undergo a stem cell transplant (SCT) for myelofibrosis? Hear firsthand experience from Bo, who was diagnosed with an MPN at age 36.
Over the past year, the investigational oral kinase inhibitor, pacritinib, has been making headlines. To help patients sort through the information and to update us on the status of pacritinib, Dr. John Mascarenhas joined us from Mount Sinai Medical Center in New York City.